BC Extra | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BC Extra | Nov 7, 2019
Clinical News

First U.S. clinical CRISPR data give early safety signal for ex vivo editing

CRISPR cleared its earliest safety hurdle with the first clinical data on the gene editing technology in the U.S., but it's still too early to tell whether that safety signal will persist and apply to...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Innovations | Sep 12, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...
BC Extra | Apr 4, 2019
Company News

Cytovant launches with Asia focus, Medigene deal

Roivant and its Sinovant affiliate launched Cytovant, a new company that will seek to develop treatments for diseases prevalent in Asia. The newco also obtained a license in Asian territories to four T cell immunotherapy...
BC Week In Review | Feb 22, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline. Merck will pay $5.85 per share in cash, or about $300 million. The price is...
BC Extra | Feb 21, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline. Merck will pay $5.85 per share in cash, or about $300 million. The price is...
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
Items per page:
1 - 10 of 132